EUVIMEDEUVIMED entdecken
Crossref

Integrating lymph node ratio into personalized radiotherapy for oral cavity squamous cell carcinoma

Linmei Zhang iD, Enzhao Zhu, Shaokang Cao, Zisheng Ai, Jiansheng Su

Head & Neck · 2025

DOI: 10.1002/hed.27938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Linmei Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Tongji Research Institute of Stomatology, Department of Prosthodontics, S…. Hauptthemen laut MEDLINE: Mouth Neoplasms, Lymph Node Ratio. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The use of postoperative radiotherapy (PORT) in patients with oral squamous cell carcinoma (OCSCC) lacks clear boundaries due to the non‐negligible toxicity accompanying its remarkable cancer‐killing effect. This study aims at validating the ability of deep learning models to develop individualized PORT recommendations for patients with OCSCC and quantifying the impact of patient characteristics on treatment selection.

Methods

Participants were categorized into two groups based on alignment between model‐recommended and actual treatment regimens, with their overall survival compared. Inverse probability treatment weighting was used to reduce bias, and a mixed‐effects multivariate linear regression illustrated how baseline characteristics influenced PORT selection.

Results

4990 patients with OCSCC met the inclusion criteria. Deep Survival regression with Mixture Effects (DSME) demonstrated the best performance among all the models and National Comprehensive Cancer Network guidelines. The efficacy of PORT is enhanced as the lymph node ratio (LNR) increases. Similar enhancements in efficacy are observed in patients with advanced age, large tumors, multiple positive lymph nodes, tongue involvement, and stage IVA. Early‐stage (stage 0–II) OCSCC may safely omit PORT.

Conclusions

This is the first study to incorporate LNR as a tumor character to make personalized recommendations for patients. DSME can effectively identify potential beneficiaries of PORT and provide quantifiable survival benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsLymph Node RatioHumansFemaleMaleMiddle AgedAgedCarcinoma, Squamous CellPrecision MedicineRadiotherapy, AdjuvantDeep LearningRetrospective StudiesNeoplasm StagingAdult

Stichwörter der Autor:innen

causal inferencedeep learningoral cavity squamous cell carcinomapostoperative radiotherapy

Autor:innen und Institutionen

  • Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Tongji Research Institute of Stomatology, Department of Prosthodontics, Stomatological Hospital and Dental School, Tongji University, Shanghai,…
  • School of Medicine, Tongji University, Shanghai, China.
  • Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Tongji Research Institute of Stomatology, Department of Oral and Maxillofacial Surgery, Stomatological Hospital and Dental School, Tongji Unive…
  • Department of Medical Statistics, School of Medicine, Tongji University, Shanghai, China.
  • Clinical Research Center for Mental Disorders, Chinese-German Institute of Mental Health, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.

ORCID-Profile: Linmei Zhang

Zitieren

APA

Zhang, L., Zhu, E., Cao, S., Ai, Z., & Su, J. (2025). Integrating lymph node ratio into personalized radiotherapy for oral cavity squamous cell carcinoma. Head & Neck. https://doi.org/10.1002/hed.27938

Vancouver

Zhang L, Zhu E, Cao S, Ai Z, Su J. Integrating lymph node ratio into personalized radiotherapy for oral cavity squamous cell carcinoma. Head & Neck. 2025. doi:10.1002/hed.27938

BibTeX
@article{Zhang2025,
  author = {Zhang, Linmei and Zhu, Enzhao and Cao, Shaokang and Ai, Zisheng and Su, Jiansheng},
  title = {Integrating lymph node ratio into personalized radiotherapy for oral cavity squamous cell carcinoma},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27938}
}
Kostenlos starten →